First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

Deloitte, in partnership with Salesforce, recently launched a sustainability-management solution focused on improving reports on environmental, social and governance (ESG) targets. The program, dubbed Greenlight Powered by Salesforce (GPBS), has been implemented into the former's operations in more than 120 countries. It was first announced last year as a collaboration that combined capabilities from data-management products of both companies and elements of code. The program is seen as an update to the Greenlight solution offered by Deloitte, which affords clients a platform that can stream their ESG reporting process. Deloitte's global chief sustainability officer, Kwasi Mitchell, explained that having the right tech solutions to achieve sustainability and net-zero goals is important. This explains why the consulting company designed an efficient and sophisticated sustainability-management solution that could serve its own needs as well as the needs of its clients. Salesforce's EVP and chief impact officer, Suzanne DiBianca, sees this partnership as a catalyst for good change. In a statement, she explained that the collaboration was a huge step forward to helping companies achieve their sustainability goals. With the unveiling of this system, enterprises such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) now have an extra option to consider as they take their implementation of ESG to the next level.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Wednesday's trading session at $0.1, up 3.0928%, on 6,800 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.1028.

Recent News

• First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) - Deloitte Partners with Salesforce to Accelerate ESG Reporting
• InvestorNewsBreaks - First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) Subsidiary Eyeing Production of Thermoelectric Generator to Replace, Improve On Vehicle Alternators
• EU Report Emphasizes Reduced Energy Costs Will Boost Economies, Support Energy Transition

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Torr Metals Inc. (TSX.V: TMET) is emerging as a key player in Canada's booming mining sector, a global leader in the production of more than a dozen essential metals, with its strong focus on early-stage discovery potential that could unlock significant value. "Headquartered in Vancouver, British Columbia, Torr is dedicated to advancing its 100% owned, district-scale projects in highly accessible and mineral-rich regions across Canada. These projects are not only poised to contribute to the clean energy revolution with critical minerals like copper but also offer the added economic benefit of potential new major gold discoveries. With existing infrastructure, year-round drilling potential, and low-cost development opportunities, Torr Metals is strategically positioned to capitalize on its exploration successes," a recent article reads.

"Building on early successes by leveraging historical data to expand known mineralization trends, Torr Metals is strategically positioned for potentially major new discoveries at Kolos Copper-Gold Project, Filion Project and Latham Copper-Gold Project, all within close proximity to established provincial and mining infrastructure… As the global demand for critical metals continues to rise, the company is well-positioned to capitalize on the opportunities presented by Canada's abundant resources."

To view the full article, visit https://ibn.fm/dQMa7

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Wednesday's trading session at $0.105, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.035/$0.195.

Recent News

• Torr Metals Inc. (TSX.V: TMET) - MiningNewsBreaks - Torr Metals Inc. (TSX.V: TMET) Positioned for Opportunities Presented by Canada's Abundant Resources
• Gold Hits New Price High as Wall Street Awaits Fed Rate Decision
• InvestorNewsBreaks - Torr Metals Inc. (TSX.V: TMET) Announces $600K Non-Brokered Private Placement

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

The event was attended by Annovis Founder, President and CEO Maria L. Maccecchini, Ph.D.

Dr. Maccecchini discussed the company's notable achievements and plans for the future and held a Q&A session with attendees.

The company CEO also participated in an expert panel discussing innovative non-amyloid approaches in Alzheimer's disease.

Recent clinical trials of the company's lead compound buntanetap obtained encouraging results and was shown to improve cognition in both Alzheimer's and Parkinson's patients.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"), participated in the H.C. Wainwright 26th Annual Global Investment Conference, held virtually, as well as in-person at the Lotte New York Palace Hotel in New York City, Sept. 9-11, 2024 (https://ibn.fm/BEBy5).

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

• Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
• Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
• Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
• Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
• Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

• Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
• Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
• Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
• Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Annovis Bio Inc. (NYSE: ANVS), closed Wednesday's trading session at $7.96, off by 0.6242197%, on 175,833 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.53/$22.49.

Recent News

• Annovis Bio Inc. (NYSE: ANVS) - Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference
• BioMedNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap
• Expert Says Alzheimer's Disease Could Be an Autoimmune Illness

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Experts warn that the Fed's decision to finally ease its monetary policy after several months of consecutive interest rate hikes may not be enough to offer a sufficient boost to clean-energy investment. The U.S. Federal Reserve began its easing cycle by cutting benchmark interest rates by 50 basis points last week, a move that was swiftly followed by central banks in Canada and several European nations. With countries such as Sweden, Switzerland and England, among many others, also easing their monetary policy, and some expected to speed up the pace, the inflationary environment triggered by the coronavirus pandemic is mostly behind us. Inflation levels have generally fallen to target ranges, and interest rates are now projected to fall even further in 2025 as the risk of a global economic slowdown rises. The clean-energy industry may also struggle to attract investments, due to bottlenecks in connecting renewables to the grid. Several green-energy power plants in the country can provide a sizable amount of green energy, but long connection lines mean many of them still can't sell their energy into the grid. The United States currently has an interconnection queue of a whopping 2.2TW, or around 1.7 times its current capacity to generate electricity. For companies that make zero-emissions vehicles, such as Mullen Automotive Inc. (NASDAQ: MULN), it is concerning that clean energies aren't being connected to the grid fast enough since such delays hold back the multiplier effects that EVs can have in reducing the rate at which damage to the climate happens.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $4.65, off by 8.284%, on 1,487,555 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.3805/$5700.00.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - Easing Monetary Policy Alone May Not Sufficiently Boost Clean-Energy Investment
• InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Shares Video Update from CEO
• InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN), Subsidiary Celebrate Production of B4 Electric Truck, CEO to Release Shareholder Update Video

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

New figures released by the CDC show that whooping cough cases have increased significantly in the United States since 2023. The rise in cases has been attributed to a reduction in rates of vaccination, which started during the pandemic. Whooping cough, also referred to as pertussis, is an infection that affects the respiratory tract. This illness is especially dangerous for infants and is highly contagious. An infectious diseases expert, Dr. William Schaffner, explains that these debilitating cough seizures are normally caused by irritation in the mucus membranes, which makes it hard for an individual to breathe. Babies may not cough, and instead, intermittently stop breathing or find it very hard to breathe. This makes their cases more severe, because their small airways are easily blocked. The DTap vaccine is recommended for kids under the age of seven, with the CDC also recommending that older children and adults receive the vaccine as well as a booster every decade. It should be noted that since babies cannot receive the vaccine until they hit the two-month mark, pregnant women are advised to get vaccinated in the third trimester of the pregnancy to protect their newborns. The surge in many infectious diseases adds more urgency to the need for biomedical companies such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to come up with immunotherapies that can roll back the toll that these diseases can have on vulnerable populations, such as babies and infants.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

• NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Wednesday's trading session at $3.47, off by 3.6111%, on 22,087 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.23/$9.60.

Recent News

• Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) - InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
• InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
• New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

In the last couple of years, silver's market has been characterized by huge fluctuations in price. This has caught the attention of traders as well as investors, with the metal showing potential for growth and exceptional resilience. Historically, the metal has seen dramatic spikes in its price, with its best price being roughly $50 an ounce. This was recorded in 1980. Even after corrections, silver has maintained a strong position, with its price remaining above $20 an ounce. This volatility presents both opportunities and challenges for those interested in trading this precious metal. Some analysts and experts in the industry have made bold predictions for the metal's future, with some expecting the price to hit $100 an ounce. Primary factors that could drive silver's price to this new high include a possible supply deficit. With the metal's industrial demand increasing and mine production finding it hard to keep up, some analysts forecast a huge shortfall in the metal's supply. This may cause its price to increase greatly as buyers compete for the available silver. Fears of currency devaluation and concerns of inflation are also contributing to bullish predictions for the metal. These bullish sentiments put exploration companies such as Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) with interests in silver mine development in a good position to attract more investor interest over the coming years.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.

Projects

Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Arizona Metals Corp. (OTCQX: AZMCF), closed Wednesday's trading session at $1.21, off by 2.3012%, on 248,395 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.20/$2.45.

Recent News

• Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) - Why Gold's Price Increase Could Continue
• UBS Analysts See Recent Copper Dip as Buying Opportunity
• Demand Concerns Sink Copper Price to Three-Month Lows

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBRsafe, developer of advanced alcohol detection and monitoring technology, has, after its recent expansion into the behavioral health market, already secured 35 new customer accounts year-to-date

The company recently unveiled a national campaign targeting more than 45,000 behavioral health decision makers across the country

The campaign is now expected to significantly build the SOBRsafe brand, grow demand and increase the company's market share

SOBRsafe (NASDAQ: SOBR), the developer of advanced transdermal alcohol detection and monitoring technology, has made substantial progress in 2024. The company has secured 35 new customer accounts this year, a substantial increase over 2023. The success followed the company's late 2023 decision to focus on the behavioral health market.

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Wednesday's trading session at $0.0877, off by 4.9837%, on 232,281 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0801/$1.24.

Recent News

• SOBRsafe Inc. (NASDAQ: SOBR) - TechMediaBreaks - SOBR Safe Inc. (NASDAQ: SOBR) Re-Inventing Continuum of Care in Behavioral Health Sector
• InvestorNewsBreaks - SOBRsafe Inc. (NASDAQ: SOBR) CEO Dave Gandini Shares Strategic Update in New Video
• InvestorNewsBreaks - SOBR Safe Inc. (NASDAQ: SOBR) Launches Comprehensive B2B Marketing Campaign to Drive Sales Growth into 2025

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF), a pioneer in providing sleep-friendly nighttime snacks, recently acquired Future Hospitality Ventures, marking a strategic pivot as it aggressively expands beyond the food sector and into the broader service industry. Specifically, the move is designed to exploit opportunities in the Robot-as-a-Service ("RaaS") market. "The acquisition of Future Hospitality Ventures is a significant step for Nightfood as it broadens its operational scope," a recent article reads. "This strategic alignment allows Nightfood to tap into new revenue streams and diversify its business portfolio. More importantly, the company is set to be a first mover in the massive foodservice and hospitality industry, which are both experiencing radical tectonic transformation due to unstoppable outside forces."

To view the full article, visit https://ibn.fm/DyVlb

Nightfood Holdings Inc. (OTCQB: NGTF) is a visionary holding company focused on identifying and capitalizing on explosive market trends within hospitality, food services and consumer packaged goods. By leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval, the company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth.

Subsidiaries

Nightfood Inc.

The company’s flagship subsidiary, Nightfood Inc., is changing the way the world snacks at night. Humans are biologically hard-wired to crave sweets and fats at night – a survival mechanism from our hunter-gatherer days. Modern consumers know bingeing excess calories before the long nightly fast is no longer necessary for survival, but exploding screen time and decreased willpower at night results in over 90% of American adults snacking between dinner and bed every week, contributing to an estimated one billion nighttime snack occasions weekly (according to SleepFoundation.org).

The most popular choices – ice cream, cookies, chips and candy – are not only unhealthy but also impair sleep quality due to their nutritional profiles. Nightfood snacks are uniquely formulated by sleep and nutrition experts to satisfy nighttime cravings AND support better sleep.

Market Opportunity

Euromonitor International projects the American snack market will grow from $150 billion in 2022 to $170 billion in 2027. Snacking between dinner and bed is estimated to account for over $60 billion annually, creating an opportunity for a multi-billion-dollar sub-category to emerge in the coming years: sleep-friendly snacking.

Nightfood is the brand pioneering that category.

Nightfood’s innovation has led to partnership overtures from global giants, including the largest food and beverage company in the world, Nestlé, with whom Nightfood completed a “test-and-learn” joint initiative in 2023.

Management believes that successfully scaling Nightfood’s 2024 direct-to-consumer launch of sleep-friendly cookies will bring the category to life, opening the door for partnerships with and potential acquisition by global snack giants seeking to lead this potential billion-dollar emerging sub-category.

Future Hospitality Ventures Holdings Inc. (d/b/a roboOp365)

Future Hospitality Ventures Holdings, operating under the brand roboOp365, is revolutionizing the hospitality industry with cutting-edge automation and robotic solutions.

roboOp365 enhances operational efficiency and guest experiences through innovative technologies, including automated culinary bot, server robots and AI-enhanced applications. roboOp365 helps hospitality providers reduce costs, streamline operations and deliver superior service by integrating these advancements.

Market Opportunity

The robots-as-a-service (RaaS) business model has gained significant traction, super-charged by the COVID-19 pandemic, which instantly catalyzed game-changing growth and application. According to Verified Market Research, the service robotics market is projected to reach $173.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 21.25%. Compared to Asia, the United States market is in the early stages of adopting these technologies, but acceptance is accelerating aggressively.

Several factors are driving this trend. Key industries such as hotels and restaurants are still struggling to rebound from the pandemic’s impact, hoping to return to pre-pandemic levels, if possible. Such recovery will largely be dependent upon service robots. In California specifically, factors such as rising labor costs, more rigorous labor laws and ongoing high turnover rates in labor-intensive sectors make it impossible for businesses to survive, thrive and compete without robotics.

Innovation Across Sectors

Nightfood Holdings Inc. is dedicated to driving innovation across its focus sectors of food services, automation and hospitality applications. In food services, the company leverages automation technology to drive operational efficiency for operators while meeting evolving consumer needs. In the hospitality industry, it’s deploying solutions that redefine guest experiences. Nightfood’s consumer-packaged goods initiatives are key to breakthrough trends in health and wellness.

Synergizing Food and Technology

The synergy of food and technology within Nightfood Holdings Inc. creates a holistic approach to innovation and automation. By integrating these areas, the company offers comprehensive solutions that address multiple facets of market needs. Its automation and artificial intelligence solutions in food service and hospitality create a seamless and enhanced consumer experience.

Through this integrated approach, Nightfood Holdings Inc. not only meets current market demands but also anticipates and influences future trends, positioning itself as a leader in innovation across these interconnected sectors. Synergies in these related and explosive categories result in operational efficiency and benefits for the company’s customers and partners and outsized upside and opportunity for its investors.

Management Team

Sean Folkson is the Chairman and President of Nightfood. He founded Nightfood when he couldn’t find a solution to his nighttime snacking problem. Recognizing the growing body of research linking nutritional intake with sleep quality, he launched the first snack brand specifically formulated to give consumers better, healthier and more sleep-friendly snacks for that peak-cravings slot between dinner and bed. He is a serial entrepreneur and problem-solver, having previously founded Specialty Equipment Direct, an online distributor of floor removal equipment, and AffiliatePros.com, a pioneering company in online affiliate marketing.

Lei Sonny Wang is the CEO of Nightfood Holdings. He is a strategist and business driver for early-stage and growth-stage companies. He is the founder and former CEO of Future Hospitality Ventures Holdings Inc., which was acquired by Nightfood Holdings Inc. At Future Hospitality, he leveraged his significant international business development experience into distribution relationships with leading global robotics manufacturers. At Nightfood, he is working to grow revenue and improve performance and profitability across all subsidiaries.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Wednesday's trading session at $0.0168, off by 0.4739336%, on 375,355 volume. The average volume for the last 3 months is 92,493 and the stock's 52-week low/high is $0.0075/$0.0425.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - InvestorNewsBreaks - Nightfood Holdings Inc. (NGTF) Evolving into Multifaceted Entity with Diversification Strategy
• InvestorNewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Announces Successful Acquisition of CarryoutSupplies.com
• Nightfood Holdings Inc. (NGTF): Spearheading the Robotics-as-a-Service ('RaaS') Revolution in Hospitality

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

• PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
• PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
• PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
• Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Wednesday's trading session at $0.1196, up 19.6%, on 227,394 volume. The average volume for the last 3 months is 69,633 and the stock's 52-week low/high is $0.065/$10.26.

Recent News

• PaxMedica Inc. (NASDAQ: PXMD) - Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients
• InvestorNewsBreaks - PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K
• Yale Study Unravels Autism, Brain Growth Patterns

Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF)

The QualityStocks Daily Newsletter would like to spotlight Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF).

Annovis Bio Inc. Overview

Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) is an active mineral exploration company engaged in the exploration and development of the company’s wholly owned multi-commodity mineral properties in Canada. The company owns the Parbec gold deposit on the Cadillac Break in Quebec and is currently exploring the Parbec property to increase the gold resource and identify a location to strip and bulk sample from surface.

In addition, the company holds the Nixon Bartleman gold property in Ontario and is also engaged in developing its wholly owned Malartic Metals Package, Quebec’s newest polymetallic battery minerals district with several areas of mineralization, one of which is the nickel, cobalt, copper and zinc mineralized Victoria structure boasting approximately 20 kilometers of strike with surface mineralization, limited drilling, road access and hydroelectric power.

Renforth is well positioned in the heart of the Abitibi Greenstone belt, which straddles the Canadian Provinces of Ontario and Quebec, on both of the Cadillac-Larder Lake and Destor-Porcupine faults – the two main structures responsible for a belt endowed with more than 300 million ounces of gold (including production, M&I reserves and resources to date), making it one of the world’s most prospective gold regions.

The Canadian Malartic Mine, one of Canada’s largest gold mines, is adjacent to each of Renforth’s brownfield Malartic area properties, the Parbec open pit gold resource and the Malartic Metals Package, which, in addition to several known battery metals mineralized structures, also hosts gold within the Pontiac sediments, a very under-explored geological setting.

The company is headquartered in Pickering, Ontario.

Projects

Parbec Gold Deposit

Renforth’s 100% owned Parbec Gold Deposit contains a gold resource designed with an open pit to capitalize on Parbec’s surface mineralization. An MRE on the project, effective December 2019 and now considered by Renforth to be obsolete, is based upon approximately 28,000 meters of drilling which occurred between 2007 and 2019.

Renforth drilled 15,000 meters of new holes in 2020 and 2021 which were not included in the MRE, but which did extend the mineralization deeper within the MRE. The 2020-21 drilling is considered to have validated an additional 13,000 meters of historic drilling from 1986-93.

The validation occurs as 10% of the historic holes were redrilled, with results comparable to the historic results in terms of geology and gold values. Any future MRE calculated at Parbec will benefit from the inclusion of the new and historic drilling.

In addition to this, Renforth’s current structural interpretation on the location of, and controls on, the gold mineralization at Parbec is materially different than the geological model for the outdated MRE. For the first time, Renforth has mapped the Pontiac contact and interpreted a hinge fold interacting with the Cadillac Break and allowing the movement of gold enriched fluids, with mineralization plunging to the south, into the Pontiac.

It is worth noting that a structural control on the adjacent, and much larger, Canadian Malartic Mine is the Sladen Fault transiting into the Pontiac. Currently, Renforth is testing this interpretation with a soil survey designed to outline an area for stripping and bulk sampling within the Pontiac south of the Cadillac Break.

Malartic Metals Package

Renforth’s wholly owned approximately 300-square-kilometer Malartic Metals Package in Quebec’s mining heartland includes surface mineralization of battery metals nickel, cobalt, copper, zinc and silver in separate structures, as well as a copper/silver discovery and gold mineralization. Lithium is also present in anomalous amounts in the sediments, though the source has not yet been located.

The property was assembled commencing in 2020 by adding claims to Renforth’s existing Malartic West property by map staking. The goal was to acquire historic gold and base metal showings, as well as pronounced magnetic anomalies, joining several of the areas of discrete historic exploration into a district scale property with several areas of interest for battery metals and a greenfield copper/silver discovery. The property benefits from its location in an established mining community, roads on the property, rail just off the property and hydroelectric power lines crossing the property, making logistics simple and the cost to operate quite low.

This is the first time this property has been assembled as it is today and actively explored. A significant portion of the property has never been explored.

Market Overview

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council. In August 2024, the market price of gold was approximately $2,435 per ounce.

Management Team

Nicole Brewster is President and CEO of Renforth Resources. During her tenure she has reconstituted the company, developed a maiden mineral resource and sold a gold deposit. She is a native of the Toronto area and has been around the mining business nearly all her life, having been raised by a successful mineral exploration geologist who worked (and is still working) around the world as an entrepreneur and geoscientist.

Ms. Brewster worked summer jobs in various segments of the mining business, which led to her employment as a contractor working in the early days of the digitization of exploration data, 3D modeling and data visualization. After working in the capital markets for a time, she returned to the mineral exploration business as a partner in a successful private firm with several employees.

Renforth Resources Inc. (OTCQB: RFHRF), closed Wednesday's trading session at $0.012, even for the day. The average volume for the last 3 months is 15,259 and the stock's 52-week low/high is $0.0068/$0.0278.

Recent News

• Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) - InvestorNewsBreaks - Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR) Releases Results from Parbec Gold Project Soil Sampling
• Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Committed to Essential Mineral Exploration on Canadian Assets
• Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) Releases Status Report in Sector Noted as 'Essential Contributor'